Spin-offs

NOSTRUM

Nostrum BioDiscovery

NOSTRUM

Nostrum BioDiscovery is the very first spin-off of the BSC. NBD is a biotech company which uses computational-based simulation and AI methods to speed up the discovery of new drugs, boosting and accelerating their route to market. It was launched on September 2016 supported by the technological know-how of BSC, IRB Barcelona, University of Barcelona, the Institució Catalana de Recerca i Estudis Avançats (ICREA). The Botín Foundation from Banco Santander brought the starting pre-seed capital.

Nearby Computing

Nearby Computing

Nearby Computing

NearbyComputing provides advanced orchestration services for IoT and 5G deployments, enabling simplified operation of IT/OT ecosystems amd the upcoming the convergence of Cloud, Fog, MEC, Edge and Networks. Its Unified Orchestration Framework bridges the gaps between existing IoT technologies and the demands that the industry, providing advanced security features, nZTP capabilities to onboard new devices, multi-tenancy support and support for cross-domain deployments. Companies across different sectors (CSPs, Oil & Gas, Industry 4.0, Smart Cities) benefit from the company's technology as it reduces their operational costs by simplifying the management of their infrastructures, automating complex processes and introducing new high-value services. The Spin-off was launched in July 2018 by an experienced team of BSC researchers, led by David Carrera, in partnership with the start-up Nearby Sensor.

MITIGA

MITIGA

MITIGA

Mitiga Solutions is focused on developing and commercializing solutions capable to evaluate and manage volcanic hazards, helping clients across multiple industries to improve their risk management. This is done by means of the exploitation of SORT-ATM, a user-friendly software capable to provide customer-based solutions for Air Traffic Management during emergency situations involving atmospheric natural hazards. Mitiga Solutions was founded in February 2018 spinning out from BSC and UPC under the lead of Dr. Alejandro Martí.

ELEM

ELEM

ELEM

ELEM Biotech is a biomedical software technology company. They create virtual humans, unleashing the power of mathematical modelling on high performance computing in the cloud. Their technology is based on Alya, the multi-physics / multi-scale parallel simulation code, which is used to conduct biomedical research "in-silico" replicating organs and physiological systems in the cloud, to test and improve medical devices and drug efficiency. This disruptive use of supercomputers in medicine in a fast, cost effective and replicable way opens a world of opportunity for medical innovation and offers the lifeline businesses in this sector and society so critically need. In ELEM, they start with cardiovascular and respiratory systems, with the vision of extend the methodology to all human physiology. ELEM was founded in July 2018 spinning out from BSC, UPC and CSIC. The project leader is Mariano Vázquez, with Guillaume Houzeaux and José María Cela as co-founders.